graph EGM comparisons
pembrolizumab (10mg/kg)titlepembrolizumab (2mg/kg)titledurvalumab alonetitleavelumab alonetitleatezolizumab alonetitleStandard of Care (SoC)titledocetaxeltitleOAK (PDL1 TC 1/2/3), 2016 NCT02008227 mNSCLC - L2 - PDL1 positive 347/337JAVELIN Lung 200 (PDL1 >1%), 2018 NCT02395172 mNSCLC - L2 - PDL1 positive 264/265ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 NCT02352948 mNSCLC - L2 - PDL1 positive 62/64KEYNOTE-010 (P:10 mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 346/343KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 151/152KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 139/152KEYNOTE-010 (P: 2mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 344/343

Pathology:  mNSCLC - L2 - PDL1 positive; 

mNSCLC - L2 - PDL1 positive
OAK (PDL1 TC 1/2/3), 2016JAVELIN Lung 200 (PDL1 >1%), 2018ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020KEYNOTE-010 (P:10 mg/kg), 2016KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg), 2016
pembrolizumab (10mg/kg)2T1T1
pembrolizumab (2mg/kg)2T1T1
durvalumab alone1T1
avelumab alone1T1
atezolizumab alone1T1
Standard of Care (SoC)0T0
docetaxel0T0T0T0T0T0T0